Transcriptomic and Genomic Approaches for Unravelling Candida albicans Biofilm Formation and Drug Resistance—An Update
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Candida albicans is an opportunistic fungal pathogen, which causes a plethora of superficial, as well as invasive, infections in humans. The ability of this fungus in switching from commensalism to active infection is attributed to its many virulence traits. Biofilm formation is a key process, which allows the fungus to adhere to and proliferate on medically implanted devices as well as host tissue and cause serious life-threatening infections. Biofilms are complex communities of filamentous and yeast cells surrounded by an extracellular matrix that confers an enhanced degree of resistance to antifungal drugs. Moreover, the extensive plasticity of the C. albicans genome has given this versatile fungus the added advantage of microevolution and adaptation to thrive within the unique environmental niches within the host. To combat these challenges in dealing with C. albicans infections, it is imperative that we target specifically the molecular pathways involved in biofilm formation as well as drug resistance. With the advent of the -omics era and whole genome sequencing platforms, novel pathways and genes involved in the pathogenesis of the fungus have been unraveled. Researchers have used a myriad of strategies including transcriptome analysis for C. albicans cells grown in different environments, whole genome sequencing of different strains, functional genomics approaches to identify critical regulatory genes, as well as comparative genomics analysis between C. albicans and its closely related, much less virulent relative, C. dubliniensis, in the quest to increase our understanding of the mechanisms underlying the success of C. albicans as a major fungal pathogen. This review attempts to summarize the most recent advancements in the field of biofilm and antifungal resistance research and offers suggestions for future directions in therapeutics development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“albicans is the third most commonly isolated microbe from bloodstream infections among hospitalized patients in the US [1].”
BackgroundThe Transcriptional Landscape of the Yeast Genome Defined by RNA Sequencing
Nagalakshmi, U., Wang, Z., Waern, K., Shou, C., Raha, D., Gerstein, M., & Snyder, M. (2008) · Science · doi:10.1126/science.1158441 · Cited by 2,479
Evolution of pathogenicity and sexual reproduction in eight Candida genomes
Butler, G., Rasmussen, M. D., Lin, M. F., Santos, M. A. S., Sakthikumar, S., Munro, C. A., Rheinbay, E., Grabherr, M., Forche, A., Reedy, J. L., et al. (2009) · Nature · doi:10.1038/nature08064 · Cited by 1,065 · cited 1×
“dubliniensis) and shows some genes involved in mating and meiosis pathways are missing throughout evolution in certain species [58].”
BackgroundCandida albicans Biofilms and Human Disease
Nobile, C. J., & Johnson, A. D. (2015) · Annual Review of Microbiology · doi:10.1146/annurev-micro-091014-104330 · Cited by 1,057
Nosocomial fungal infections: epidemiology, diagnosis, and treatment
Perlroth, J., Choi, B., & Spellberg, B. (2007) · Medical Mycology · doi:10.1080/13693780701218689 · Cited by 738 · cited 1×
“Vaccination is another potential strategy in preventing invasive fungal infections, particularly on high-risk groups with identifiable risk factors [102,103].”
BackgroundA Recently Evolved Transcriptional Network Controls Biofilm Development in Candida albicans
Nobile, C. J., Fox, E. P., Nett, J. E., Sorrells, T. R., Mitrovich, Q. M., Hernday, A. D., Tuch, B. B., Andes, D. R., & Johnson, A. D. (2012) · Cell · doi:10.1016/j.cell.2011.10.048 · Cited by 711
Candida albicans Biofilms Produce Antifungal-Tolerant Persister Cells
LaFleur, M. D., Kumamoto, C. A., & Lewis, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00684-06 · Cited by 521
Mukherjee, P. K., Chandra, J., Kuhn, D. M., & Ghannoum, M. A. (2003) · Infection and Immunity · doi:10.1128/iai.71.8.4333-4340.2003 · Cited by 511
Ramage, G. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf049 · Cited by 468
Dispersion as an Important Step in the Candida albicans Biofilm Developmental Cycle
Uppuluri, P., Chaturvedi, A. K., Srinivasan, A., Banerjee, M., Ramasubramaniam, A. K., Köhler, J. R., Kadosh, D., & Lopez-Ribot, J. L. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000828 · Cited by 432 · cited 1×
“Importantly, a previous study had shown that the dispersed cells are predominantly yeast cells, with associated enhanced adherence, filamentation capacity, biofilm formation, increased resistance to azole drugs, and are more pathogenic than their planktonic counterparts [22].”
BackgroundMechanisms of Candida Biofilm Drug Resistance
Taff, H. T., Mitchell, K. F., Edward, J. A., & Andes, D. R. (2013) · Future Microbiology · doi:10.2217/fmb.13.101 · Cited by 422 · cited 1×
“Among these, although β-1,3 glucan is a minor constituent, it is the chief matrix polysaccharide linked to biofilm resistance to antifungals as it could block drug diffusion [19].”
BackgroundPutative Role of β-1,3 Glucans in Candida albicans Biofilm Resistance
Nett, J., Lincoln, L., Marchillo, K., Massey, R., Holoyda, K., Hoff, B., VanHandel, M., & Andes, D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01056-06 · Cited by 407 · cited 1×
“One of the more prominent factors is the ability of this species to effectively pump out drugs via its efflux pumps mechanism [41].”
BackgroundEvolution of antifungal-drug resistance: mechanisms and pathogen fitness
Anderson, J. B. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1179 · Cited by 375
Candida albicans Als3, a multifunctional adhesin and invasin
Liu, Y., & Filler, S. G. (2011) · Eukaryotic Cell · doi:10.1128/ec.00279-10 · Cited by 354 · cited 1×
“The Hwp1 and also the Als3 proteins are produced predominantly during hypha formation, to allow for the adhesion of the fungal cells either to the host cells or to a substrate surface [8].”
BackgroundEffect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study
Lara, H. H., Romero-Urbina, D. G., Pierce, C., Lopez-Ribot, J. L., Arellano-Jiménez, M. J., & Jose-Yacaman, M. (2015) · Journal of Nanobiotechnology · doi:10.1186/s12951-015-0147-8 · Cited by 323 · cited 1×
“albicans biofilm cells and inhibit filamentation [96].”
Role of dimorphism in the development of Candida albicans biofilms
BAILLIE, G. S., & DOUGLAS, L. J. (1999) · Journal of Medical Microbiology · doi:10.1099/00222615-48-7-671 · Cited by 304
Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms
Robbins, N., Uppuluri, P., Nett, J., Rajendran, R., Ramage, G., Lopez-Ribot, J. L., Andes, D., & Cowen, L. E. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002257 · Cited by 291
In Vitro Activity of Caspofungin against Candida albicans Biofilms
Bachmann, S. P., VandeWalle, K., Ramage, G., Patterson, T. F., Wickes, B. L., Graybill, J. R., & López-Ribot, J. L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3591-3596.2002 · Cited by 288
Recent insights into Candida albicans biofilm resistance mechanisms
Mathé, L., & Van Dijck, P. (2013) · Current Genetics · doi:10.1007/s00294-013-0400-3 · Cited by 271
Portrait of Candida albicans Adherence Regulators
Finkel, J. S., Xu, W., Huang, D., Hill, E. M., Desai, J. V., Woolford, C. A., Nett, J. E., Taff, H., Norice, C. T., Andes, D. R., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002525 · Cited by 228 · cited 2×
“Meanwhile, the deletion of Zcf28p, Zfu2p and Crz2p is only able to disrupt biofilm formation on catheters in animal models [27].”
BackgroundRajendran, R., Sherry, L., Nile, C. J., Sherriff, A., Johnson, E. M., Hanson, M. F., Williams, C., Munro, C. A., Jones, B. J., & Ramage, G. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.09.018 · Cited by 228
Candida albicans-Induced Epithelial Damage Mediates Translocation through Intestinal Barriers
Allert, S., Förster, T. M., Svensson, C.-M., Richardson, J. P., Pawlik, T., Hebecker, B., Rudolphi, S., Juraschitz, M., Schaller, M., Blagojevic, M., et al. (2018) · mBio · doi:10.1128/mbio.00915-18 · Cited by 208 · cited 1×
“albicans, is crucial for this process [10].”
Vediyappan, G., Rossignol, T., & d'Enfert, C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01638-09 · Cited by 183 · cited 1×
“As such, studies have shown fluconazole activity is enhanced upon digestion of β-1,3 glucan while amphotericin B activity is enhanced by the degradation of eDNA [11,42,84].”
BackgroundAn expanded regulatory network temporally controls C andida albicans biofilm formation
Fox, E. P., Bui, C. K., Nett, J. E., Hartooni, N., Mui, M. C., Andes, D. R., Nobile, C. J., & Johnson, A. D. (2015) · Molecular Microbiology · doi:10.1111/mmi.13002 · Cited by 173
Siles, S. A., Srinivasan, A., Pierce, C. G., Lopez-Ribot, J. L., & Ramasubramanian, A. K. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00680-13 · Cited by 120
Fox, E. P., & Nobile, C. J. (2012) · Transcription · doi:10.4161/trns.22281 · Cited by 114 · cited 1×
“These regulators were discovered via screening a mutant library and in vivo studies in animal models [24,25].”
BackgroundIn Vitro and In Vivo Activity of a Novel Antifungal Small Molecule against Candida Infections
Wong, S. S. W., Kao, R. Y. T., Yuen, K. Y., Wang, Y., Yang, D., Samaranayake, L. P., & Seneviratne, C. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085836 · Cited by 107 · cited 1×
“albicans yeast-to-hypha transition [90].”
Potent In Vitro Synergism of Fluconazole and Osthole against Fluconazole-Resistant Candida albicans
Li, D.-D., Chai, D., Huang, X.-W., Guan, S.-X., Du, J., Zhang, H.-Y., Sun, Y., & Jiang, Y.-Y. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00436-17 · Cited by 42 · cited 1×
“, catalase encoded by CAT1 and mitochondrial glycosylase encoded by OGG1); CTN1 (carnitine acetyltransferase) and ICL1 (isocitrate lyase) were upregulated [66]”
Background
Cited by
Resistance of Candida to azoles and echinocandins worldwide
Pristov, K. E., & Ghannoum, M. A. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.03.028 · Cited by 706
“Azoles do not interferewith host cell walls because themajor target componentsdchitin, glucan and mannandare absent from the human body, and because of the difference in structures between ergosterol and cholesterol (which is the main component in the host cell walls) [1,13].”
BackgroundInfluentialCandida albicans biofilms and polymicrobial interactions
Ponde, N. O., Lortal, L., Ramage, G., Naglik, J. R., & Richardson, J. P. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2020.1843400 · Cited by 281
Candida albicans biofilm growth and dispersal: contributions to pathogenesis
Wall, G., Montelongo-Jauregui, D., Vidal Bonifacio, B., Lopez-Ribot, J. L., & Uppuluri, P. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.04.001 · Cited by 263
“albicans biofilms as compared to their planktonic counterparts, which mostly highlighted the role of metabolism in biofilm growth[10,28].”
BackgroundMechanism of Candida pathogenesis: Revisiting the vital drivers
Mba, I. E., & Nweze, E. I. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03912-w · Cited by 143
Pentland, D. R., Davis, J., Mühlschlegel, F. A., & Gourlay, C. W. (2021) · npj Biofilms and Microbiomes · doi:10.1038/s41522-021-00238-z · Cited by 28
Metadata
- Authors
- Chong, P., Chin, V., Wong, W., Madhavan, P., Yong, V., & Looi, C.
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2018-11-07
- Volume
- 9
- Issue
- 11
- Pages
- 540
- ISSN
- 2073-4425 (ISSN-L)
- OpenAlex
- W2900143075
- Cited by
- 57
- References
- 28
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.